Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep ApneaGlobeNewsWire • 05/09/22
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome TherapeuticsPRNewsWire • 05/09/22
Axsome Therapeutics, Inc.'s (AXSM) CEO Herriot Tabuteau on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/02/22
Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 05/02/22
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of MigrainePRNewsWire • 05/02/22
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 04/27/22
Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022PRNewsWire • 04/25/22
Axsome (AXSM) Up 27.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/31/22